These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 1578372

  • 21. Prevention of canine coronary artery thrombosis with echistatin, a potent inhibitor of platelet aggregation from the venom of the viper, Echis carinatus.
    Shebuski RJ, Ramjit DR, Sitko GR, Lumma PK, Garsky VM.
    Thromb Haemost; 1990 Dec 28; 64(4):576-81. PubMed ID: 2084943
    [Abstract] [Full Text] [Related]

  • 22. Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.
    Parry TJ, Huang Z, Chen C, Connelly MA, Perzborn E, Andrade-Gordon P, Damiano BP.
    Blood Coagul Fibrinolysis; 2011 Dec 28; 22(8):720-6. PubMed ID: 21986468
    [Abstract] [Full Text] [Related]

  • 23. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting.
    Hertfelder HJ, Bös M, Weber D, Winkler K, Hanfland P, Preusse CJ.
    Semin Thromb Hemost; 2005 Dec 28; 31(4):426-40. PubMed ID: 16149021
    [Abstract] [Full Text] [Related]

  • 24. Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina.
    Klootwijk P, Lenderink T, Meij S, Boersma H, Melkert R, Umans VA, Stibbe J, Müller EJ, Poortermans KJ, Deckers JW, Simoons ML.
    Eur Heart J; 1999 Aug 28; 20(15):1101-11. PubMed ID: 10413640
    [Abstract] [Full Text] [Related]

  • 25. Inhibition of repetitive thrombus formation in the stenosed canine coronary artery by enoxaparin, but not by unfractionated heparin.
    Leadley RJ, Kasiewski CJ, Bostwick JS, Bentley R, Dunwiddie CT, Perrone MH.
    Arterioscler Thromb Vasc Biol; 1998 Jun 28; 18(6):908-14. PubMed ID: 9633930
    [Abstract] [Full Text] [Related]

  • 26. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
    Freund M, Mantz F, Nicolini P, Gachet C, Mulvihill J, Meyer L, Beretz A, Cazenave JP.
    Thromb Haemost; 1993 May 03; 69(5):515-21. PubMed ID: 8322274
    [Abstract] [Full Text] [Related]

  • 27. Antithrombotic activity of Z4A5, a new platelet glycoprotein IIb/IIIa receptor antagonist evaluated in a rabbit arteriovenous shunt thrombosis model.
    Jing BB, Li YX, Zhang H, Ren ST, Wang M, Li YP, Zang WJ, Wang B.
    Thromb Res; 2011 Nov 03; 128(5):463-9. PubMed ID: 21924458
    [Abstract] [Full Text] [Related]

  • 28. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ, Sitko GR, Holahan MA, Stranieri MT, Glass JD, Askew BC, McIntyre CJ, Claremon DA, Baldwin JJ, Hartman GD, Gould RJ, Lynch JJ.
    J Pharmacol Exp Ther; 1997 May 03; 281(2):677-89. PubMed ID: 9152373
    [Abstract] [Full Text] [Related]

  • 29. Prevention of early reocclusion after thrombolysis of copper coil-induced thrombi in the canine carotid artery: comparison of PEG-hirudin and unfractionated heparin.
    Rübsamen K, Hornberger W.
    Thromb Haemost; 1996 Jul 03; 76(1):105-10. PubMed ID: 8819261
    [Abstract] [Full Text] [Related]

  • 30. Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis.
    Lewis GD, Witzke C, Colon-Hernandez P, Guerrero JL, Bloch KD, Semigran MJ.
    J Am Coll Cardiol; 2006 Apr 04; 47(7):1471-7. PubMed ID: 16580539
    [Abstract] [Full Text] [Related]

  • 31. Inhibition by D-MePhe-Pro-Arg-H (GYKI-14766) of thrombus growth in experimental models of thrombosis.
    Bagdy D, Szabó G, Barabás E, Bajusz S.
    Thromb Haemost; 1992 Aug 03; 68(2):125-9. PubMed ID: 1412156
    [Abstract] [Full Text] [Related]

  • 32. Nonpeptide glycoprotein IIb/IIIa inhibitors: 14: oral antithrombotic efficacy of L-738,167 in a conscious canine model of coronary artery electrolytic injury.
    Cook JJ, Glass JD, Sitko GR, Holahan MA, Stupienski RF, Wallace AA, Stump GL, Hand EL, Askew BC, Hartman GD, Gould RJ, Lynch JJ.
    Circulation; 1997 Aug 05; 96(3):949-58. PubMed ID: 9264506
    [Abstract] [Full Text] [Related]

  • 33. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin.
    Anand SS, Yusuf S, Pogue J, Ginsberg JS, Hirsh J, Organization to Assess Strategies for Ischemic Syndromes Investigators.
    Circulation; 2003 Jun 17; 107(23):2884-8. PubMed ID: 12796128
    [Abstract] [Full Text] [Related]

  • 34. Dual effects of sulfated D-galactans from the red algae Botryocladia occidentalis preventing thrombosis and inducing platelet aggregation.
    Farias WR, Nazareth RA, Mourão PA.
    Thromb Haemost; 2001 Dec 17; 86(6):1540-6. PubMed ID: 11776325
    [Abstract] [Full Text] [Related]

  • 35. Antithrombotic effect of Z4A5 on coronary thrombosis in a canine model of acute unstable angina.
    Jing BB, Li YX, Zhang H, Ren ST, Wang M, Li YP, Shen XL, Wang YL, Zang WJ, Wang B.
    Br J Pharmacol; 2013 Jun 17; 169(4):848-59. PubMed ID: 23083032
    [Abstract] [Full Text] [Related]

  • 36. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis.
    Rebello SS, Bentley RG, Morgan SR, Kasiewski CJ, Chu V, Perrone MH, Leadley RJ.
    Br J Pharmacol; 2001 Aug 17; 133(7):1190-8. PubMed ID: 11487531
    [Abstract] [Full Text] [Related]

  • 37. Anti-thrombosis effect of diosgenin extract from Dioscorea zingiberensis C.H. Wright in vitro and in vivo.
    Gong G, Qin Y, Huang W.
    Phytomedicine; 2011 Apr 15; 18(6):458-63. PubMed ID: 21036572
    [Abstract] [Full Text] [Related]

  • 38. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
    Finkle CD, St Pierre A, Leblond L, Deschenes I, DiMaio J, Winocour PD.
    Thromb Haemost; 1998 Feb 15; 79(2):431-8. PubMed ID: 9493603
    [Abstract] [Full Text] [Related]

  • 39. Effects of heparin, dermatan sulfate and of their association on the inhibition of venous thrombosis growth in the rabbit.
    Carrie D, Caranobe C, Gabaig AM, Larroche M, Boneu B.
    Thromb Haemost; 1992 Dec 07; 68(6):637-41. PubMed ID: 1287877
    [Abstract] [Full Text] [Related]

  • 40. A primate model (Macaca mulatta) to study the pharmacokinetics of heparin and its fractions.
    Fareed J, Kumar A, Rock A, Walenga JM, Davis P.
    Semin Thromb Hemost; 1985 Apr 07; 11(2):138-54. PubMed ID: 4035364
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.